Article Text

Download PDFPDF
Resolution of the recent performance problem of Abbott LCx Chlamydia trachomatis assay. Issues of repeat testing for confirmation of chlamydial infection
  1. H Mallinson,
  2. J Hopwood,
  3. K Mutton
  1. PHLS Liverpool, University Hospital at Aintree, Lower Lane, Liverpool L9 7AL, UK
  1. Correspondence to:
 Dr Mallinson;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In February 2001, Abbott Laboratories issued a device correction notice to users of their LCx Chlamydia trachomatis assay suggesting that initially reactive ligase chain reaction (LCR) tests should be repeated on the same sample to validate the test result. A recent alert (December 2001) from the Medical Devices Agency (MDA, DA2001(09)) indicates that the device correction is still in force and points out the resource implications where retesting is required. We offer some data on LCR performance characteristics during this period and before.

The Department of Health pilot study on “Opportunistic screening for genital chlamydial infection in Portsmouth and Wirral” ran for a year up to October 2000. …

View Full Text